Skip to content

Application of Near Infrared-Phthalocyanine Green Imaging System in Da Vinci XI Robotic Gastric Cancer Surgery: a Single Center, Prospective Controlled Clinical Trial

Application of Near Infrared-Phthalocyanine Green Imaging System in Da Vinci XI Robotic Gastric Cancer Surgery: a Single Center, Prospective Controlled Clinical Trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026542
Enrollment
Unknown
Registered
2019-10-13
Start date
2019-12-01
Completion date
Unknown
Last updated
2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

control group:traditional laparoscopic indocyanine green near-infrared light imaging

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18-75 years, gender is not limited; 2. All patients were diagnosed as gastric cancer by gastroscopy and histopathological examination before surgery. According to the eighth edition of AJCC, the preoperative clinical stage was cT1-4N0-3M0. 3. The primary lesion is feasible for gastric cancer D2 resection; 4. ECOG physical status score 0-1; 5. Preoperative patients volunteered to participate in the study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergic to ICG or iodine 2. There is distant metastasis of lung, brain, bone, liver and peritoneum, and the peritoneal lavage fluid is cytologically positive; 3. Combined with severe heart, pulmonary dysfunction can not tolerate laparoscopic surgery; 4. Need to combine organ resection; 5. Suffering from other serious diseases, including cardiovascular, respiratory, renal, or liver diseases, combined with poorly controlled hypertension, diabetic patients, mental disorders or diseases; 6. Preoperative radiotherapy, chemotherapy, targeted therapy, immunotherapy and other treatments; 7. Emergency surgery under bleeding, obstruction or perforation; 8. Previous history of merger with other malignant tumors.

Design outcomes

Primary

MeasureTime frame
Number of lymph nodes detected and positive rate;Intraoperative blood loss;operation time;Navigation of vessels and structures;Surgical quality rating;Postoperative complication rate during hospitalization;3-year disease-free survival;3-year overall survival;

Secondary

MeasureTime frame
Postoperative hospital stay;Hospital costs;

Countries

China

Contacts

Public ContactLi Zhengrong

The First Affiliated Hospital of Nanchang University

lzr13@foxmail.com+86 15979128160

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026